Clinical Trial Update: Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIA study of CART19 cells in chemotherapy-resistant or refractory CD19+ leukemia and lymphoma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CART19 (CD19-directed chimeric antigen receptor T cells)

Snippet

Sponsor: University of Pennsylvania | Conditions: B Cell Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-23